Robert M. Prins
James Madison University(US)University of California, Los Angeles(US)UCLA Health(US)UCLA Health(US)Ronald Reagan UCLA Medical Center(US)UCLA Medical Center(US)University of California System(US)Los Angeles Medical Center(US)Parker Institute for Cancer Immunotherapy(US)National Cancer Institute(US)The University of Texas Southwestern Medical Center(US)Stanford University(US)
Publications by Year
Research Areas
Immunotherapy and Immune Responses, Glioma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immune cells in cancer
Most-Cited Works
- → Cancer-associated IDH1 mutations produce 2-hydroxyglutarate(2009)4,077 cited
- → Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma(2019)1,356 cited
- → Immunotherapy response assessment in neuro-oncology: a report of the RANO working group(2015)751 cited
- → Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment(2005)541 cited
- → First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma(2018)531 cited
- Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.(2001)